We are live on ! Find out more
BIOR

Biora Therapeutics, Inc. Common Stock
BIOR

Delisted

BIOR was delisted on the 10th of December, 2024.

Back to rankings

44 hedge funds and large institutions have $24.1M invested in Biora Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

85% more call options, than puts

Call options by funds: $1.03M | Put options by funds: $556K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 46 → 44 (-2)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

30% less capital invested

Capital invested by funds: $34.5M → $24.1M (-$10.4M)

Holders
44
Holders Change
-2
Holders Change %
-4.35%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
12
Reduced
6
Closed
8
Calls
$1.03M
Puts
$556K
Net Calls
+$471K
Net Calls Change
-$772K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$585K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$142K
3
Jane Street
Jane Street
New York
+$23K
4
Wolverine Trading
Wolverine Trading
Illinois
+$18.2K
5
Citadel Advisors
Citadel Advisors
Florida
+$16.6K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$241K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$141K
3
SM
Sabby Management
Florida
-$90.4K
4
Morgan Stanley
Morgan Stanley
New York
-$39.1K
5
EGM
Engineers Gate Manager
New York
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Principal Financial Group
26
Principal Financial Group
Iowa
$9K +$540 +3 +4%
HF
27
HRT Financial
New York
$8K -$4.86K -27 -27%
Osaic Holdings
28
Osaic Holdings
Arizona
$8K – – –
Cambridge Investment Research Advisors
29
Cambridge Investment Research Advisors
Iowa
$7K – – –
LPL Financial
30
LPL Financial
California
$6K – – –
CG
31
Cutler Group
California
$6K +$5.04K +28 +112%
CIBC Private Wealth Group
32
CIBC Private Wealth Group
Georgia
$5K – – –
TRCT
33
Tower Research Capital (TRC)
New York
$5K +$900 +5 +14%
VF
34
Virtu Financial
New York
$5K +$7.38K +41 New
XS
35
XR Securities
Illinois
$5K +$7.74K +43 New
WA
36
WealthTrust Axiom
Pennsylvania
$4K – – –
AF
37
Advisornet Financial
Minnesota
$2K – – –
EGM
38
Engineers Gate Manager
New York
– -$8K -46 Closed
Group One Trading
39
Group One Trading
Illinois
– -$6.66K -37 Closed
CAPTRUST Financial Advisors
40
CAPTRUST Financial Advisors
North Carolina
– -$2K -9 Closed
Citigroup
41
Citigroup
New York
– -$1K -4 Closed
UBS Group
42
UBS Group
Switzerland
– -$720 -4 Closed
Simplex Trading
43
Simplex Trading
Illinois
– -$360 -2 Closed
TAM
44
Tucker Asset Management
Colorado
– -$350 -2 Closed
Rockefeller Capital Management
45
Rockefeller Capital Management
New York
– +$180 +1 New
Bank of America
46
Bank of America
North Carolina
– +$360 +2 New
RAM
47
Riggs Asset Management
Pennsylvania
– +$360 +2 New
SPIA
48
Steward Partners Investment Advisory
New York
– +$540 +3 New
1
2

BIOR Hedge Fund Activity: Q3 2022 in Review

44 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q3 2022, worth a combined $24.1M — down 30% from $34.5M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of BIOR and 7 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 12 added.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $585K. The largest seller was Millennium Management, cutting an estimated $241K.

  • 44 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q3 2022, down from 46 in Q2 2022.
  • Funds reported $24.1M of Biora Therapeutics, Inc. Common Stock stock for Q3 2022, down 30% quarter-over-quarter.
  • 7 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q3 2022 and 8 closed out, a net change of -1 holder.
  • The largest Biora Therapeutics, Inc. Common Stock buyer in Q3 2022 was GSA Capital Partners, an estimated $585K added.
  • The largest Biora Therapeutics, Inc. Common Stock seller in Q3 2022 was Millennium Management, an estimated $241K sold.

Based on aggregated 13F filings for Q3 2022.